Name | HUMAN MENOPAUSAL GONADOTROPHIN |
Synonyms | Lepori Menopur Menogon hMG Fuji MENOTROPIN Menogon HP Humegon 100 HUMAN MENOPAUSAL GONADOTROPHIN MENOPAUSAL GONADOTROPHIN, HUMAN URINE |
CAS | 61489-71-2 |
Molecular Formula | C9H18O |
Molar Mass | 142.23862 |
Storage Condition | 2-8℃ |
MDL | MFCD00131230 |
Physical and Chemical Properties | Chemical properties white or off-white powder, soluble in water. |
Use | Uses for biochemical and clinical research, for the treatment of infertility. |
Abstract:
objective: to observe the curative effect of Erzhi tiaojing decoction combined with urinary gonadotropin (HMG) in the treatment of anovulatory infertility, and to explore its mechanism. Methods: 53 cases of anovulatory infertility patients were randomly divided into two to tiaojing combined with HMC group (treatment group, 28 cases, 67 cycles) and HMG group (control group, 25 cases, 66 cycles), determination of HMG cycle dosage, dominant follicle number and follicle score, compared two groups of cycle ovulation rate, pregnancy rate and cycle pregnancy rate, results: the treatment group HMG cycle dosage was significantly lower than the control group. The number of dominant follicles, follicle score, pregnancy rate and cycle pregnancy rate on the day of HCG injection were significantly higher than those in the control group. Conclusion: two to tiaojing prescription and HMG can play a synergistic role, complementary length, complement each other, from the macroscopic overall coordination of the body's endocrine environment, which is conducive to pregnancy.
Key words:
second to meridians tonifying kidney urotrophin ovulatory disorder
DOI:
10.3969/j.issn.1672-397X.2006.01.019
cited:
year:
2006
201110244410
Public/Announcement Number:
CN102293756 A
applicant (patent):
Bengbu Fengyuan tuoshan Pharmaceutical Co., Ltd.
inventor:
cited:
Abstract:
The invention relates to a urotropin freeze-dried powder for injection and a preparation method thereof. In each 1 mg of the freeze-dried powder for injection, the active ingredient is 60-200 units in terms of follicle-stimulating hormone titer, and the auxiliary material is L-arginine, mannitol and phosphate buffered saline are composed in a weight ratio of 4-8:20-40:2.0-6.0. The formulation of the present invention enables the preparation process to avoid the long-term presence of urotropin in the aqueous solution state, and reduces the freeze-drying time and increases the stability of the urotropin freeze-dried powder injection.
CN201921640764.1
application date:
2019-09-29
Public/Announcement Number:
CN210993233U
Public/announcement date:
2020.07.14
applicant (patent):
Hangzhou Herber Biotechnology Co., Ltd.
inventor:
National and provincial code:
CN330185
Abstract:
The utility model discloses a filter press device for processing urotrophin, which relates to the technical field of urotrophin processing, the inside of the device housing is fixedly connected with a filter press housing, the upper part of the outer surface of the filter press housing is fixedly connected with a fixing sleeve by a nut, and the outer surface of the fixing sleeve is fixedly connected with a fixing bracket, the lower portion of the filter press housing is provided with a plurality of through holes, the bottom of the filter press housing is fixedly connected with a mounting plate, and the bottom of the mounting plate is fixedly connected with a support column. The utility model can carry out extrusion filtration through the filter press shell, and the fixation of the filter press shell can be ensured by the fixed sleeve and the fixed bracket, so as to prevent the displacement of the filter press shell from shaking, thereby affecting the filter press of the product, the installation and replacement of the support column is facilitated by the installation plate, and the filter press is facilitated